Spyre Therapeutics, Inc.
NASDAQSpyre Therapeutics enters June with an unusual combination: a stock that has drifted 6% lower on the week while the Street is broadly bullish, insider selling has been persistent, and short positions have quietly climbed to their highest level in six weeks. Short sellers have been adding steadily. At 15.4% of the free float, short interest is up roughly a full percentage point…
Snapshot as of 22 Jun 2026
Spyre Therapeutics enters June with an unusual combination: a stock that has drifted 6% lower on the week while the Street is broadly bullish, insider selling has been persistent, and short positions have quietly…
Spyre Therapeutics heads into its May 8 earnings call in a charged position — the Street is racing to lift targets after strong Phase 2 data, while the CEO, CFO, and CMO all hit the sell button on the same day the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SYRE — free to start on ORTEX.
Sign up for free →Open SYRE on ORTEX